Portal de investigación
Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Donday, M. Garcia
- Riestra, S.
- Lucendo, A. J.
- Benitez, J. M.
- Navarro-Llavat, M.
- Barrio, J.
- Morales-Alvarado, V. J.
- Busquets, D.
- Carnerero, E. Leo
- Ochoa, O. Merino
- Castillejo, O. Nantes
- Navarro, P.
- Van Domselaar, M.
- Casbas, A. Gutierrez
- Alonso-Abreu, I.
- Mejuto, R.
- Salazar, L. Fernandez
- Martin-Arranz, M. D.
- Pineda, R.
- Sampedro, M. J.
- Nilsson, K. Serra
- Assakali, A. Bouhmidi
- Batista, L.
- Villafranca, C. Munoz
- Rodriguez-Lago, I.
- Santos, D. S. Ceballos
- Guerra, I.
- Manosa, M.
- Jimenez, I. Marin
- Mendoza, I. Vera
- Acosta, M. Barreiro-De
- Domenech, E.
- Esteve, M.
- Garcia-Sanchez, V.
- Panes, J.
- Gisbert, J. P.
- Behalf Exit Study Grp Geteccu
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Chaparro,M,Donday,MG,Riestra,S,Lucendo,AJ,Benitez,JM,Navarro,M,Barrio,J et al. Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT). GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND:OXFORD UNIV PRESS. 2023 p.p. 50-54.